Enter term or phrase to begin searching:
You do not have the latest version of Flash installed on your computer. Please click here to download the free player.
Undetectable is the goal of treatment for all patients5
Greater Antiviral Response with FUZEON
Greater Antiviral Response with FUZEON
Greater Antiviral Response with FUZEON
"...the goal of therapy
should be the achievement of HIV RNA levels below 50 copies/mL, even for highly treatment-experienced patients..."
2006 IAS Recommendations
View data from clinical trials to see how FUZEON can make undetectable possible for more treatment-experienced patients.
"When I started FUZEON, I had 72 T cells. Now I have more than 900."
Individual results with regimens including FUZEON may be different than those included here.
Individualized, supplemental education, self-injection training and follow-up support can help patients start and maintain a FUZEON-based regimen.
Welcome Healthcare Professionals
The first in a class of antiretroviral drugs called fusion inhibitors, FUZEON targets HIV before it enters and infects the CD4 cell. Clinical trial results of FUZEON in combination with other antiretroviral agents in treatment-experienced patients have shown reductions in viral load and increases in CD4 counts.

Indication
FUZEON (enfuvirtide) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. This indication is based on results from two controlled studies of 48 weeks' duration. Subjects enrolled were treatment-experienced adults; many had advanced disease. There are no studies of FUZEON in antiretroviral-naïve patients.

Click here to read the full Prescribing Information for FUZEON.

Click here to read the Important Safety Information.
  1. Haubrich R, DeMasi R, Thommes J. Improved virologic response in three class-experienced patients when an active boosted protease inhibitor is combined with enfuvirtide (ENF). 43rd Annual Meeting of IDSA. October 7-8, 2005. San Francisco, CA. Poster 785.
  2. Data on file (Ref. 118-059), Hoffmann-La Roche Inc., Nutley, NJ 07110.
  3. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment of HIV-1 infected patients at 48 weeks (RESIST): an analysis of combined data from two randomized open-label trials. Lancet. 2006;368(9534):466-475.
  4. Lazzarin A, Queiroz-Telles F, Frank I, et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. 16th International AIDS Conference. August 13-18, 2006. Toronto, Canada. Abstract TUAB0104.
  5. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296(7):827-843.
©2003-2007 Roche Laboratories Inc. and Trimeris, Inc.